Cargando…
CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models
We have previously shown that transgenic mice carrying a mutant human APP but deficient in CD40L, display a decrease in astrocytosis and microgliosis associated with a lower amount of deposited Aβ. Furthermore, an anti-CD40L treatment causes a diminution of Aβ pathology in the brain and an improved...
Autores principales: | Laporte, Vincent, Ait-Ghezala, Ghania, Volmar, Claude-Henry, Mullan, Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1456952/ https://www.ncbi.nlm.nih.gov/pubmed/16504112 http://dx.doi.org/10.1186/1742-2094-3-3 |
Ejemplares similares
-
Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease
por: Paris, Daniel, et al.
Publicado: (2010) -
Chronic Anatabine Treatment Reduces Alzheimer’s Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD
por: Verma, Megha, et al.
Publicado: (2015) -
Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD
por: Verma, Megha, et al.
Publicado: (2015) -
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
por: Schweig, Jonas Elias, et al.
Publicado: (2017) -
Flavonoids lower Alzheimer's Aβ production via an NFκB dependent mechanism
por: Paris, Daniel, et al.
Publicado: (2011)